Drugs / TT-232
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00735332 | Aug 2008 → Dec 2009 | melanoma | Thallion Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-232 | ChEMBL registry synonym — accepted as the source's own label CHEMBL539934 ↗ |
| Known as | TLN-232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00735332 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL539934 ↗ |
| Route | Intravenous | “21 day continuous IV administration of TLN-232” NCT00735332 ↗ |